Ubiquitin-negative mini-pick-like bodies in the dentate gyrus in p3011 tauopathy

Journal of Alzheimer's Disease

Volumn 5, Issue 6, 2003, Pages 445-454

  Ferrer, Isidro ^a,b,e   Hernández, Isabel ^c   Puig, Berta ^a   Rey, María Jesús ^b   Ezquerra, Mario ^b,d   Tolosa, Eduardo ^b,d   Boada, Merce ^c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Barcelona   (Spain)

^c Inst Catala de Neurociencies Apl   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

TAU PROTEIN; UBIQUITIN;

ADULT; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; CASE REPORT; DEGENERATIVE DISEASE; DEMENTIA; DENTATE GYRUS; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TAUOPATHY;

EID: 0347134480     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/jad-2003-5604     Document Type: Article

References (45)

1. E. Adamec, J.R. Murrell, M. Takao, W. Hobbs, R.A. Nixon, B. Ghetti and J.P. Vonsattel, P301L tauopathy: confocal inmunofluorescence study of perinuclear aggregation of the mutated protein, J. Neurol. Sci. 200 (2002), 85-93.
2. C. Atzori, B. Ghetti, R. Piva, A.N. Srinivasan, P. Zolo, M.B. Delisle, S.S. Mirra and A. Migheli, Activation of JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis, J. Neuropathol. Exp. Neurol. 60 (2001), 1190-11197.
3. S. Barghorn, Q. Zheng-Fischofer, M. Ackmann, J. Biernat, M. von Bergn, E.M. Mandelkow and E. Mandelkow, Structure, microtubule interactions and paired helical filament aggregations by tau mutants of frontotemporal dementias, Biochemistry 39 (2000), 11714-11721.
4. B.J. Bassam, G. Caetano-Anolles and P.M. Gresshoff, Fast and sensitive staining of DNA in polyacrylamide gels, Annal. Biochem. 196 (1991), 80-83.
5. R.V. Bhat and S.L. Budd, GSK-3beta signaling: casting a wide net in Alzheimer's disease, Neurosignals 11 (2002), 251-261.
6. T.D. Bird, D. Nochlin, P. Poorkaj, M. Charrier, J. Kayre, H. Payani, E. Reskind, T.H. Lampe, E. Nemens, P.S. Boyer and G.D. Schellenberg, A clinical pathological comparison of three families with frontotemporal dementia and identical mutations in the tau gene (P301L), Brain 122 (1999), 741-756.
7. L. Buée, T. Bussire, V. Buée-Cherrer, A. Delacourte and P.R. Hof, Tau protein isoforms, phosphorylation and role in neurodegenerative disorders, Brain Res Rev 33 (2000), 95-130.
8. O. Bugiani, J.R. Murrell, G. Giacone, M. Hasegawa, G. Ghigo, M. Tabaton, M. Morbin, A. Primavera, F. Carella, C. Solaro, M. Grisoli, M. Savoiardo, M.G. Spillantini, F. Tagliavini, M. Goedert and B. Ghetti, Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau, J. Neuropathol. Exp. Neurol. 58 (1999), 667-677.
9. P. Cohen and S. Frame, The renaissance of GSK3, Nat. Rev. 2 (2001), 769-776.
10. C. Conrad, C. Vianna and M. Freeman et al., A polymorphic gene nested within an intron of the tau gene: implications for Alzheimer's disease, Proc Natl Acad Sci USA 99 (2002), 7751-7756.
11. I. Ferrer, M. Barrachina, M. Tolnay, M.J. Rey, N. Vidal, M. Carmona, R. Blanco and B. Puig, Phosphorylated protein kinases associated with neuronal and glial tau deposits in argyrophilic grain disease, Brain Pathol 13 (2003), 62-78.
12. I. Ferrer, M. Barrachina and B. Puig, Glycogen synthase kinase-3 (GSK-3) is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration, Acta Neuropathol 104 (2002), 658-664.
13. I. Ferrer, R. Blanco, M. Carmona and B. Puig, Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies, J. Neural. Transm. 108 (2001), 1397-1415.
14. I. Ferrer, R. Blanco, M. Carmona, R. Ribera, E. Goutan, B. Puig, M.J. Rey, A. Cardozo, F. Viñals and T. Ribalta, Phosphorylated MAP kinase (ERK1, ERK2) expression is associated with early tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration, Brain Pathol 11 (2001), 144-158.
15. I. Ferrer, P. Pastor, M.J. Rey, E. Muñoz, B. Puig, E. Pastor, R. Oliva and E. Tolosa, Tau phosphorylation and kinase activation in familial tauopathy linked to delN296 mutation, Neuropathol. Appl. Neurobiol. 29 (2003), 23-34.
16. B. Ghetti, M.L. Hutton and Z.K. Wszolek, Frontotemporal dementia and parkinsonism linked to chromosome 17 associated with tau gene mutations (FTDP-17T), in: Neurodegeneration: The molecular pathology of dementia and movement disorders, D. Dickson, ed., ISN Neuropath Press, Basel 2003, pp. 86-102.
17. M. Goedert, R. Jakes and E. Vanmechelen, Monoclonal antibody AT8 recognizes tau protein phosphorylated at both serine 202 and threonine 205, Neurosci. Lett. 189 (1995), 167-169.
18. J. Götz, Tau and transgenic animal models, Brain Res. Rev. 35 (2001), 266-286.
19. J. Götz, F. Chen, R. Barmettler and R.M. Nitsch, Tau filament formation in transgenic mice expressing P301L tau, J. Biol. Chem. 276 (2001), 529-534.
20. M. Hasegawa, M.J. Smith and M. Goedert, Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly, FEBS Lett 437 (1998), 207-210.
21. M. Hutton, C.L. Lendon, P. Rizzu, M. Baker, S. Froelich, H. Houlden, S. Pickering-Brown, S. Chakraertz, A. Isaacs, A. Gover, J. Hackett, J. Adamson, S. Lincoln, D. Dickson, P. Davies, R.C. Petersen, M. Stevans, I. de Graaf, E. Wantens, J. van Baren, M. Hillebrand, J.M. Joosse, V. Nowotny and P. Heutriak et al., Association of a missense and 5′ splice-site mutations in tau with the inherited dementia FTDP-17, Nature 393 (1998), 702-705.
22. M. Hutton, H. Lewis, D. Dickson, S.H. Yen and E. McGowen, Analysis of tauopathies with transgenic mice, Trends Mol. Med. 7 (2001), 467-470.
23. E.M. Ingram and M.G. Spillantini, Tau gene mutations: dissecting the pathogenesis of FTDP-17, Trends Mol. Med. 8 (2002), 556-562.
24. M.D. Kaytor and H.T. Orr, The GSK3β signaling cascade and neurodegenerative disease, Curr. Opin. Neurobiol. 12 (2002), 275-278.
25. R.B. Knowles, J. Chin, C.T. Ruff and B.T. Hyman, Demonstration by fluorescence resonance energy transfer of a close association between activated MAP kinase and neurofibrillary tangles: Implications for MAP kinase activation in Alzheimer disease, J. Neuropathol. Exp. Neurol. 58 (1999), 1090-1098.
26. T. Kobayashi, H. Mori, Y. Okuma, D.W. Dickson, N. Cookson, Y. Tsuboi, Y. Motoi, R. Tanaka, N. Miyashita, M. Anno, H. Narabayashi and Y. Mizzuno, Contrasting genotypes of the tau gene in two phenotypically distinct patients with P301L mutation of frontotemporal dementia and parkinsonism linked to chromosome 17, J. Neurol. 249 (2002), 669-675.
27. M.V.Y. Lee, M. Goedert and J.Q. Trojanowski, Neurodegenerative tauopathies, Annu. Rev. Neurosci. 24 (2001), 1121-1159.
28. J. Lewis and D.V. Dickson, Transgenic animal models of tauopathies, in: Neurodegeneration: The molecular pathology of dementia and movement disorders, D. Dickson, ed., ISN Neuropath Press, Basel 2003, pp. 150-154.
29. J. Lewis, E. McGowan, J. Rockwood, H. Melrose, P. Nacharaju, M. van Slegtenhorst, K. Gwinn-Hardy, M. Paul Murphy, M. Baker, X. Yu, J. Hardy, A. Corral, W.L. Lin, S.H. Yen, D.W. Dickson, P. Davies and M. Hutton, Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau proteins, Nat. Genet. 25 (2000), 402-405.
30. W.L. Lin, J. Lewis, S.H. Yen, M. Hutton and D.W. Dickson, Filamentous tau oligodendrocytes and astrocytes of transgenic mice expressing the human tau isoform with the P301L mutation, Am. J. Pathol. 162 (2003), 213-218.
31. S.S. Mirra, J.R. Murrell, M. Gearing, M.G. Spillantini, M. Goedert, A. Crowther, A.I. Levey, R. Jones, J. Green, J.M. Shioffner, B.H. Wainer, M.L. Schmidt, J.Q. Trojanowski and B. Guetti, Tau pathology in a family with a P301L mutation in tau, J. Neuropathol. Exp. Neurol. 58 (1999), 335-345.
32. J.R. Murrell, M.G. Spillantini, P. Zolo, M. Guazzelli, M.J. Smith, M. Hasegawa, F. Redi, A. Crowther, P. Pietrini, B. Ghetti and M. Goedert, Tau gene mutation G389R causes a tauopathy with abundant Pick Body-like inclusions and axonal deposits, J. Neuropathol. Exp. Neurol. 58 (1999), 1207-1226.
33. Z.S. Nasreddine, M. Loginov, L.N. Clark, J. Lamarche, B.L. Miller, A. Lamontagne, V. Zhurakeva, M.V. Lee, K.L. Wilhelmen and P.H. Geshwind, From genotype to phenotype: a clinical pathological, and biochemical investigation of frontotemporal dementia and parkinsonism (FTDP-17) caused by the P301L mutation, Ann. Neurol. 45 (1999), 704-715.
34. J.J. Pei, E. Braak, H. Braak, I. Grundke-Iqbal, K. Iqbal, B. Winblad and R.F. Cowburn, Distribution of glycogen synthase kinase 3 beta (GSK-3β) for Alzheimer disease neurofibrillary tangle, J. Neuropathol. Exp. Neurol. 58 (1999), 1010-1119.
35. G. Perry, H. Roder, A. Nunomura, A. Takeda, A.L. Friedlich, X. Zhu, A.L. Raina, N. Holbrook, S.L. Siedlak, P.L.R. Harris and M.A. Smith, Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal tau phosphorylation, NeuroReport 10 (1999), 2411-2415.
36. P. Rizzu, M. Joosse, R. Ravid, A. Hoogeveen, W. Kamphorst, J.C. van Swieten, R. Willemsen and P. Huetink, Mutation-dependent aggregation of tau protein and its selective depletion from the soluble fraction in brain of p310L FTDP-17 patients, Hum. Mol. Genet. 9 (2000), 3075-3082.
37. M.G. Spillantini, R.A. Crowther, W. Kamphorst, P. Heutink and J.C. van Swieten, Tau pathology in two Dutch families with mutations in the microtubule-binding region of tau, Am. J. Pathol. 153 (1998), 1359-1363.
38. M.G. Spillantini and M. Goedert, Tau protein pathology in neurodegenerative diseases, Trends Neurosci 21 (1998), 428-433.
39. T. Togo, N. Sahara, S.H. Yen, N. Cookson, T. Ishizawa, M. Hutton, R. De Silva, A. Lees and D.W. Dickson, Argyrophilic grain disease is a sporadic 4-repeat tauopathy, J. Neuropathol. Exp. Neurol. 61 (2002), 547-556.
40. M. Tolnay and A. Probst, Review: Tau protein: pathology in Alzheimer's disease and related disorders, Neuropathol. Appl. Neurobiol, 25 (1999), 171-187.
41. R.H. Walker, J. Friedman, J. Wiener, R. Hobler, K. Gwinn-Hardy, A. Adam, J. DeWolfe, R. Gibbs, M. Baker, M. Farrer, M. Hutton and J.A. Hardy, A family with a tau P301L mutation presenting with parkinsonism, Parkinsonism Relat Disord 9 (2002), 121-123.
42. S. H. Yen, M. Hutton, M. deTure, L.W. Ko and P. Nacharaju, Fibrillogenesis of tau: insights from tau missense mutations in FTDP-17, Brain Pathol 9 (1999), 695-705.
43. X. Zhu, H.G. Lee, A.K. Raina, G. Perry and M.A. Smith, The role of mitogen-activated protein kinase pathways in Alzheimer's disease, Neurosignals 1 (2002), 270-281.
44. X. Zhu, A.K. Raina, C.A. Rottkamp, G. Aliev, G. Perry, H. Boux and M.A. Smith, Activation and re-distribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease, J. Neurochem. 76 (2001), 435-441.
45. X. Zhu, C.A. Rottkamp, H. Boux, A. Takeda, G. Perry and M.A. Smith, Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease, J. Neuropathol. Exp. Neurol. 59 (2000), 880-888.